Celldex Therapeutics, Inc. $CLDX Shares Sold by Braidwell LP

Braidwell LP trimmed its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 67.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 436,646 shares of the biopharmaceutical company’s stock after selling 919,436 shares during the period. Braidwell LP’s holdings in Celldex Therapeutics were worth $16,248,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Quantinno Capital Management LP increased its position in shares of Celldex Therapeutics by 178.7% in the 1st quarter. Quantinno Capital Management LP now owns 65,744 shares of the biopharmaceutical company’s stock valued at $2,085,000 after purchasing an additional 42,158 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Celldex Therapeutics by 70.8% in the 1st quarter. Bank of America Corp DE now owns 708,647 shares of the biopharmaceutical company’s stock valued at $22,478,000 after purchasing an additional 293,759 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Celldex Therapeutics by 78.7% during the 1st quarter. First Trust Advisors LP now owns 68,470 shares of the biopharmaceutical company’s stock worth $2,172,000 after purchasing an additional 30,157 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Celldex Therapeutics during the first quarter worth $1,210,000. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Celldex Therapeutics during the first quarter worth $929,000.

Analysts Set New Price Targets

A number of analysts have weighed in on CLDX shares. Cantor Fitzgerald cut their price target on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 22nd. Barclays upped their price objective on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. HC Wainwright reissued a “buy” rating and set a $42.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 15th. Morgan Stanley boosted their target price on Celldex Therapeutics from $40.00 to $46.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Guggenheim upped their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $56.08.

Celldex Therapeutics Stock Performance

CLDX opened at $39.48 on Thursday. Celldex Therapeutics, Inc. has a one year low of $21.77 and a one year high of $45.14. The stock has a market capitalization of $3.10 billion, a P/E ratio of -9.08 and a beta of 0.84. The business’s 50-day simple moving average is $38.88 and its 200-day simple moving average is $33.65.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post -4.13 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.